Quick Takeaways
- CTSO - Cytosorbents Corp has 11 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 11 Insiders of Cytosorbents Corp
- Symbol
- CTSO on Nasdaq
- Location
- Princeton, NJ
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Apr 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Cytosorbents Corp executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Phillip P. Chan | Chief Executive Officer, Director | $949,096 | Mixed | 18 Nov 2025 | ||
| Vincent Capponi | President and COO | $766,268 | Mixed | 08 Aug 2025 | ||
| Kathleen P. Bloch | Chief Financial Officer | $708,812 | Mixed | 02 Apr 2024 | ||
| Peter J. Mariani | Chief Financial Officer | $538,113 | Mixed | 08 Aug 2025 | ||
| Efthymios Deliargyris | Chief Medical Officer | $473,025 | Mixed | 08 Aug 2025 | ||
| Alex D'Amico | Chief Financial Officer | $279,300 | Mixed | 07 Aug 2023 | ||
| Kraus al | Director | $188,921 | Mixed | 06 Feb 2023 | ||
| Michael G. Bator | Director | $151,273 | Mixed | 08 Aug 2025 | ||
| Alan D. Sobel | Director | $147,757 | Mixed | 08 Aug 2025 | ||
| Edward Raymond Jones | Director | $88,834 | Mixed | 08 Aug 2025 | ||
| Jiny Kim | Director | $77,819 | Mixed | 08 Aug 2025 |
Top shareholders of Cytosorbents Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Thomas A. Satterfield Jr. |
13D/G
|
— |
6.6%
|
3,998,867
|
$4,638,686 | $0 | 13 Jan 2025 | |
| Avenue Venture Opportunities Fund, L.P. |
13D/G
|
Avenue Capital Management II, L.P. |
5.7%
|
3,755,273
|
$4,356,117 | $0 | 26 Jun 2024 | |
| AVENIR CORP |
13D/G
13F
|
Company |
8.3%
|
5,230,099
|
$3,817,972 | +$1,559,392 | 31 Dec 2025 | |
| Skylands Capital, LLC |
13D/G
13F
|
Company |
4.8%
|
3,002,702
|
$3,483,134 | +$256,453 | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13D/G
13F
|
The Vanguard Group · Company |
3.1%
|
1,949,551
|
$2,261,479 | -$2,261,479 | 31 Mar 2025 | |
| Neuberger Berman Group LLC |
13F
|
Company |
2.6%
|
1,625,640
|
$1,039,597 | — | 31 Dec 2025 | |
| Phillip P. Chan |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
1,801,027
mixed-class rows
|
$949,096 | — | 18 Nov 2025 | |
| CM Management, LLC |
13F
|
Company |
2.3%
|
1,476,500
|
$943,779 | — | 31 Dec 2025 | |
| Vincent Capponi |
3/4/5
|
President and COO |
—
mixed-class rows
|
940,888
mixed-class rows
|
$766,268 | — | 08 Aug 2025 | |
| Kathleen P. Bloch |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
633,098
mixed-class rows
|
$708,812 | — | 02 Apr 2024 | |
| Peter J. Mariani |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
693,363
mixed-class rows
|
$538,113 | — | 08 Aug 2025 | |
| BlackRock, Inc. |
13F
|
Company |
1.2%
|
770,551
|
$492,536 | — | 31 Dec 2025 | |
| Efthymios Deliargyris |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
600,491
mixed-class rows
|
$473,025 | — | 08 Aug 2025 | |
| Sargent Investment Group, LLC |
13F
|
Company |
0.97%
|
612,000
|
$391,190 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.96%
|
603,767
|
$386,034 | — | 31 Dec 2025 | |
| Pathstone Holdings, LLC |
13F
|
Company |
0.79%
|
499,955
|
$319,571 | — | 31 Dec 2025 | |
| Alex D'Amico |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
210,000
|
$279,300 | — | 07 Aug 2023 | |
| Kraus al |
3/4/5
|
Director |
—
class O/S missing
|
142,046
|
$188,921 | — | 06 Feb 2023 | |
| Michael G. Bator |
3/4/5
|
Director |
—
mixed-class rows
|
227,031
mixed-class rows
|
$151,273 | — | 08 Aug 2025 | |
| Alan D. Sobel |
3/4/5
|
Director |
—
mixed-class rows
|
213,657
mixed-class rows
|
$147,757 | — | 08 Aug 2025 | |
| CIBC Private Wealth Group LLC |
13F
|
Company |
0.27%
|
172,649
|
$110,357 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.25%
|
159,293
|
$101,820 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.24%
|
149,279
|
$95,419 | — | 31 Dec 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.24%
|
148,374
|
$95,000 | — | 31 Dec 2025 | |
| Edward Raymond Jones |
3/4/5
|
Director |
—
mixed-class rows
|
110,834
mixed-class rows
|
$88,834 | — | 08 Aug 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.21%
|
130,419
|
$83,447 | — | 31 Dec 2025 | |
| Jiny Kim |
3/4/5
|
Director |
—
mixed-class rows
|
99,819
mixed-class rows
|
$77,819 | — | 08 Aug 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.18%
|
116,480
|
$74,455 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.18%
|
115,272
|
$73,659 | — | 31 Dec 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.17%
|
108,702
|
$69,482 | — | 31 Dec 2025 | |
| NWF Advisory Services Inc. |
13F
|
Company |
0.17%
|
104,139
|
$66,566 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.16%
|
100,120
|
$63,997 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.15%
|
92,540
|
$59,151 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.13%
|
83,363
|
$53,286 | — | 31 Dec 2025 | |
| Key Client Fiduciary Advisors, LLC |
13F
|
Company |
0.12%
|
78,457
|
$50,150 | — | 31 Dec 2025 | |
| Waverly Advisors, LLC |
13F
|
Company |
0.09%
|
55,556
|
$35,511 | — | 31 Dec 2025 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.08%
|
48,000
|
$30,682 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.06%
|
38,706
|
$24,732 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.06%
|
35,952
|
$22,980 | — | 31 Dec 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.05%
|
29,682
|
$18,973 | — | 31 Dec 2025 | |
| EP Wealth Advisors, LLC |
13F
|
Company |
0.04%
|
28,000
|
$17,898 | — | 31 Dec 2025 | |
| Compound Planning, Inc. |
13F
|
Company |
0.04%
|
27,443
|
$17,542 | — | 31 Dec 2025 | |
| Kestra Advisory Services, LLC |
13F
|
Company |
0.04%
|
25,700
|
$16,427 | — | 31 Dec 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.04%
|
23,066
|
$14,744 | — | 31 Dec 2025 | |
| Creative Planning |
13F
|
Company |
0.03%
|
21,295
|
$13,612 | — | 31 Dec 2025 | |
| Seelaus Asset Management LLC |
13F
|
Company |
0.03%
|
17,300
|
$11,058 | — | 31 Dec 2025 | |
| Merit Financial Group, LLC |
13F
|
Company |
0.02%
|
15,297
|
$9,778 | — | 31 Dec 2025 | |
| FIRST NATIONAL BANK OF OMAHA |
13F
|
Company |
0.02%
|
15,225
|
$9,777 | — | 31 Dec 2025 | |
| Texas Capital Bank Wealth Management Services Inc |
13F
|
Company |
0.02%
|
11,000
|
$7,031 | — | 31 Dec 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.02%
|
10,780
|
$7,000 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Cytosorbents Corp
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Phillip P. Chan | CTSO | Common Stock | Award | 7.23% | 100,000 | 1,482,963 | 18 Nov 2025 | Direct | ||
| Phillip P. Chan | CTSO | Common Stock | Award | 8.27% | 105,600 | 1,382,963 | 08 Aug 2025 | Direct | ||
| Phillip P. Chan | CTSO | Stock Option (Right to Buy) | Award | 136,400 | 136,400 | 08 Aug 2025 | Direct | |||
| Edward Raymond Jones | CTSO | Stock Option (Right to Buy) | Award | 22,000 | 22,000 | 08 Aug 2025 | Direct | |||
| Michael G. Bator | CTSO | Stock Option (Right to Buy) | Award | 44,000 | 44,000 | 08 Aug 2025 | Direct | |||
| Peter J. Mariani | CTSO | Common Stock | Award | 15.3% | 71,500 | 538,113 | 08 Aug 2025 | Direct | ||
| Peter J. Mariani | CTSO | Stock Option (Right to Buy) | Award | 90,000 | 90,000 | 08 Aug 2025 | Direct | |||
| Jiny Kim | CTSO | Stock Option (Right to Buy) | Award | 22,000 | 22,000 | 08 Aug 2025 | Direct | |||
| Vincent Capponi | CTSO | Common Stock | Award | 13.2% | 89,100 | 766,268 | 08 Aug 2025 | Direct | ||
| Vincent Capponi | CTSO | Stock Option (Right to Buy) | Award | 111,100 | 111,100 | 08 Aug 2025 | Direct | |||
| Efthymios Deliargyris | CTSO | Common Stock | Award | 17.4% | 70,000 | 473,025 | 08 Aug 2025 | Direct | ||
| Efthymios Deliargyris | CTSO | Stock Option (Right to Buy) | Award | 95,000 | 95,000 | 08 Aug 2025 | Direct | |||
| Alan D. Sobel | CTSO | Stock Option (Right to Buy) | Award | 22,000 | 22,000 | 08 Aug 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.